The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy

References

• Ng TL, Hutton B. Clemons M Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea? Oncologist. 2015;20:576–583.
   PubMed Web of Science ®Google Scholar
• Navari RM. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf. 2016;15:343–356.
   PubMed Web of Science ®Google Scholar
• Navari RM. Aapro M antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. New Engl J Med. 2016;374:1356–1367.
   PubMed Web of Science ®Google Scholar
• Aapro M, Carides A, Rapoport BL. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist. 2015;20:450–458.
   PubMed Web of Science ®Google Scholar
• Navari RM. Profile of netupitant/palonosetron fixed dose combination (NEPA) and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther. 2015;9:155–161.
   PubMed Web of Science ®Google Scholar
• Navari RM, Schwartzberg L. Evolving role of neurokinin 1 receptor antagonists for chemotherapy-induced nausea and vomiting. Oncol Targets Ther. 2018;11:6459–6478.
   PubMed Web of Science ®Google Scholar
• Navari RM, Qin R, Ruddy KJ, et al. Loprinzi CL olanzapine for the prevention of chemotherapy-induced nausea and vomiting. New Engl J Med. 2016;375:134–142.
   PubMed Web of Science ®Google Scholar
• Hocking CM. Kichenadasse G olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer. 2014;22:1143–1151.
   PubMed Web of Science ®Google Scholar
• Navari RM. Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharm. 2014;722:180–186.
   PubMed Web of Science ®Google Scholar
• Navari RM. Treatment of chemotherapy-induced nausea. Community Oncol. 2012;9:20–26.
   Google Scholar
• Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2017;35:3240–3261.
   PubMed Web of Science ®Google Scholar
• National comprehensive cancer network NCCN clinical practice guidelines in oncology: antiemesis – version 1. 2019. Pennsylvania (USA): NCCN.
   Google Scholar
• Herrstedt J, Roila F, Warr D, et al. 2016 Updated MASCC ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer. 2017;25:277–288.
   PubMed Web of Science ®Google Scholar
• Roila F, Warr D, Hesketh PJ, et al. 2016 Updated MASCC ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy. Suppo Care Cancer. 2017;25:289–294.
   PubMed Web of Science ®Google Scholar
• Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs. 2000;60:533–546.
   PubMed Web of Science ®Google Scholar
• Merck Inc. Emend (aprepitant) capsules, or oral use and Emend (aprepitant) or oral suspension [prescribing information]. Whitehouse Station, NJ: Merck & Co; 2017 May.
   Google Scholar
• Tesaro Inc. Varubi (rolapitant) tablets, for oral use and Varubi (rolapitant) injectable emulsion, for intravenous use [prescribing information]. Waltham, MA: Tesaro Inc; 2018 March.
   Google Scholar
• Helsinn Inc. Alkynzeo (netupitant and palonosetron) capsules, for oral use and (fosnetupitant and palonosetron) for injection [prescribing information]. Iselin, NJ: Helsinn Therapeutics; 2018.
   Google Scholar
• Merck Co. Emend (fosaprepitant) for injection, for intravenous use [prescribing information]. Whitehouse Station, NJ: Merck & Co; 2018 April.
   Google Scholar
• Heron Inc. Cinvanti (aprepitant) injectable emulsion, for intravenous use. San Diego, CA: Heron Therapeutics; 2017.
   Google Scholar
• Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol–EASE. J Clin Oncol. 2011;29:1495–1501.
   PubMed Web of Science ®Google Scholar
• Ottoboni T, Keller MR, Cravets M, et al. Bioequivalence of HTX-019 (aprepitant IV) and Fosaprepitant in healthy subjects: a phase I, open label, randomized, 2-way crossover evaluation. Drug Des Devel Ther. 2018;12:429–435.
   PubMed Web of Science ®Google Scholar
• Ottoboni T, Lauw M, Keller MR, et al. Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects. Future Oncol. 2018;14:2849–2859.
   PubMed Web of Science ®Google Scholar
• Rizzi A, Campi B, Camarda V, et al. In vitro and in vivo pharmacological characterization of the novel NK-1 receptor selective antagonist netupitant. Peptides. 2012;37:86–97.
   PubMed Web of Science ®Google Scholar
• Rossi G, Tilkola SO, Rudengren C, et al. A positron emission tomography study to assess the degree of neurokinin-1 receptor occupancy in the human brain after single doses of netupitant to healthy male subjects. J Clin Oncol. 2012;30(abstract):9054.
   Google Scholar
• Spinelli T, Calcagneli S. Giuliano C Netupitant PET Imaging and ADME studies in humans. J Clin Pharm. 2014;54:97–108.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25:1340–1346.
   PubMed Web of Science ®Google Scholar
• Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014;25:1328–1333.
   PubMed Web of Science ®Google Scholar
• Gralla RJ, Bosnjak SM, Hontsa A, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014;25:1333–1339.
   PubMed Web of Science ®Google Scholar
• Schwartzberg L, Aapro M, Hesketh PJ, et al. Do NK-1 receptor antagonists contribute to nausea control? Evaluation of the novel NEPA fixed-dose combination of NK-1 receptor antagonist plus a 5-HT3 receptor antagonist from pivotal trials. Support Care Cancer. 2014;22:107. Abstract 161
   Google Scholar
• Duffy RA, Morgan C, Naylor R, et al. Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK-1 receptor antagonist with centrally-mediated antiemetic effects in ferrets. Pharmacol Biochem Behav. 2012;102:95–100.
   PubMed Web of Science ®Google Scholar
• Poma A, Christensen J, Pertikis H, et al. Rolapitant and its major metabolite do not affect the pharmacokinetics of midazolam, a sensitive cytochrome P450 3A4 substrate. Support Care Cancer. 2013;21:S154. Abstract 441
   Google Scholar
• Poma A, Christensen J, Davis J, et al. Phase 1 positron emission tomography (PET) study of the receptor occupancy of rolapitant, a novel NK-1 receptor antagonist. J Clin Oncol. 2014;32:abstr e20690.
   Web of Science ®Google Scholar
• Rapoport B, Chua D, Poma A, et al. Study of rolapitant, a novel, long acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Support Care Cancer. 2015 May 5;23:3281–3288.
   Web of Science ®Google Scholar
• Schwartzberg L, Modiana M, Rapoport B, et al. Safety and efficacy assessment of rolapitant for the prevention of chemotherapy‐induced nausea and vomiting following administration of moderately emetogenic chemotherapy in cancer patients in a randomized phase 3 trial. Lancet Oncol. 2015;16:1071–1078.
   PubMed Web of Science ®Google Scholar
• Rapoport B, Chasen M, Gridelli C, et al. Safety and efficacy assessment of rolapitant for the prevention of chemotherapy‐induced nausea and vomiting following administration of cisplatin-based highly emetogenic chemotherapy in cancer patients in two randomized phase 3 trials. Lancet Oncol. 2015;16:1079–1089.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang ZY, Powers D, et al. Bioequivalence of intravenous and oral rolapitant: results from a randomized, open-label pivotal study. J Clin Pharmacol. 2017;57:1600–1606.
   PubMed Web of Science ®Google Scholar
• van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxanePharmacology. Invest New Drugs. 2001;19:125–141.
   PubMed Web of Science ®Google Scholar
• Ten Tije AJ, Verweij J, Loos WJ. Sparreboom A Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42:665–685.
   PubMed Web of Science ®Google Scholar
• Wu G, Yeung S, Chen F. Compatibility and stability of rolapitant injectable emulsion admixed with intravenous palonosetron hydrochloride. Int J Pharm Compd. 2017;21:76–82.
   PubMedGoogle Scholar
• Wu G, Yeung S, Chen F. Compatibility and stability of rolapitant injectable emulsion admixed with intravenous palonosetron hydrochloride Injection and dexamethasone sodium phosphate. Int J Pharm Compd. 2018;22:76–85.
   PubMedGoogle Scholar
• Schwartzberg L, Andric Z, Kowalski D, et al. Phase 3 safety evaluation of an intravenous formulation of NEPA, a novel fixed antiemetic combination of fosnetupitant and palonosetron. Ann Oncol. 2017;28:545. (abstract 1547PD)
   Web of Science ®Google Scholar
• Schwartzberg L, Andric Z, Kowalski D, et al. Phase III safety evaluation of an intravenous formulation of NEPA, a novel fixed antiemetic combination of fosnetupitant and palonosetron, over multiple cycles. J Clin Oncol. 2017;35(abstract):122).
   Google Scholar
• Zhang L, Lu S, Feng J, et al. A randomized phase III study r\evaluating the efficacy of a single dose of NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Ann Oncol. 2018;29:452–458.
   PubMed Web of Science ®Google Scholar
• Navari RM, Rapaport BL, Powers D, et al. Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy. Cancer Med. 2018;7:2943–2950.
   Web of Science ®Google Scholar